set in Medical Technology

Insurance Industry Teleconference on Swine Flu Pandemic Set for May 13

BERWYN, Pa., May 4 /PRNewswire/ -- Just hours after the World Health Organization warned that a Swine Flu or A/H1N1 pandemic is imminent, a prominent insurance law firm announced it will host a teleconference for insurance executives working to address this urgent global risk. "As we've seen ...

Next Generation Proton Therapy System for Cancer Treatment Set for Release This Year

LITTLETON, Mass., Feb. 26 /PRNewswire/ -- Still River Systems announced today the successful operation of the world's highest field, high energy cyclotron magnet. Still River's magnet is the key technical element for reducing the size and cost of the particle accelerator that will deliver proton t...

GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009.

WHEAT RIDGE, Colo., Nov. 24 /PRNewswire-FirstCall/ -- GeneThera, Inc. (Pink Sheets: GTHR.PK), announces it will soon begin offering its Real Time PCR test for Johne's disease through its Wheat Ridge, Colo. laboratory. GeneThera is set to begin offering its Johne's disease testing service a...

Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial

Novartis notified of data set closing, Top-line results expected in November SEATTLE, Nov. 3 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has closed the data set for preliminary analysis of the primary e...

Velos Set to Clear 50 Percent Market Penetration of Large U.S. Clinical Research Sites by Year End

FREMONT, Calif., Aug. 7 /PRNewswire/ -- Velos, Inc., the recognized leader and trusted resource for clinical trial management information systems for large investigator sites, today announced it will cross the 50 percent market penetration threshold by year end. The company's flagship product,...

Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) First Quarter 2008 Financial Results Call Set for May 6

VENLO, The Netherlands, April 29 /PRNewswire-FirstCall/ -- QIAGEN N.V. (Nasdaq: QGEN ) today announced the Webcast of its first quarter 2008 financial results call. The Webcast will take place at 9:30 a.m. EDT on Tuesday, May 6, and will include remarks by Peer M. Schatz, President and Chief ...

FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008

-- ARI-2243 is a highly potent DPP-4 inhibitor being developed for the treatment of Type II diabetes -- ARI-2243 produced a compelling 2.5% reduction in HbA1c in refractory diabetic animal model -- ARI-2243 is a first-in-class "soft drug" conferri...

10 Million Square Feet of Turf Set to be Treated in 2008 in Response to MRSA Outbreaks Nationwide

ROCHESTER HILLS, Mich., Jan. 8 /PRNewswire/ -- CSG/SportsCoatings, today announced approximately 10 million square feet of synthetic turf will be treated with its industry-leading antimicrobial coating, TurfAide(TM), in 2008 -- up from 1.5 million square feet in 2007. The exponential increas...

Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants

Study released at the Pediatric Academic Societies' Annual Meeting This Month in Toronto Shows That Switching to Masimo SET Pulse Oximetry Technology Can Reduce the Risk Associated with ROP by 40% IRVINE, Calif., May 30, 2007 /PRNewswire/ -- Masimo, the inventor of Pulse CO-Oximetry and Read-Throu...

Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer

...rmed over the last twenty-five years indicate that KRAS plays an important role in cell growth regulation. In mCRC, EGFR transmits signals through a set of intracellular proteins. Upon reaching the nucleus, these signals instruct the cancer cell to reproduce and metastasize, leading to cancer progressi...

NewCardio Announces Master Services Agreement With Dedicated Phase I

...rially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2008 and relate to our business plan, our business strategy, develo...

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

...cial condition could suffer; (vi) advances by competitors, particularly if unanticipated; and (vii) certain other important risks and uncertainties set forth in the company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 6, 2009, the company's Quarterly Report o...

Popular Breast Cancer Drug Used with Certain Antidepressants Puts New Jersey Women at Risk

...vate Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake n...

Diabetes Gene Raises Odds of Lower Birth Weight

... diabetes also predisposes children to having a lower birth weight. The finding sheds light on a possible genetic influence on how prenatal events may set the stage for developing diabetes in later childhood or adulthood. Researchers from The Children's Hospital of Philadelphia and the University ...

Lilly and New York City Mayor Michael R. Bloomberg Announce Lilly Agrees to be First Tenant of East River Science Park; Issue Urgent Call for Healthcare Reform that Protects Innovation and Jobs

...s never fully capitalized on its assets to create a thriving commercial bioscience industry and the jobs that come with it," said Mayor Bloomberg. "We set out to create the East River Science Park to provide today's bioscience companies with the state-of-the-art commercial lab space they need to locate a...

July 2009 Mayo Clinic Women's HealthSource Highlights Food Storage Safety, Energy Therapies and Vitamins and Minerals

...una or pasta salads. Cooked or uncooked fish should be tossed after one to two days. The same goes for fresh sausage and uncooked ground beef. set the temperature. A refrigerator temperature should be at or below 40 F. The freezer should be kept at 0 F. If in doubt, throw it out. Any fo...

Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)

...l of developing novel combinations of direct-acting antivirals for the treatment of hepatitis C." The company plans to report the full data set from this study at a scientific meeting later this year. About IDX184 IDX184 is a novel, liver-targeted 2'-methyl guanosine nucleotide ...

Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study

...rted outcomes. Subjects in both treatment groups are continuing in an open-ended extension study. The companies plan to present the full data set at a major medical meeting and submit the data for publication. About Diabetes Diabetes affects more than 23 million people in the U.S...

Prospective Clinical Advantages of Trabecular Metal(TM) Technology Highlighted in Comparative Study

...or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports. Readers of this document are cautioned not to place undue reliance on these forward-looking statements, since, while w...

Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimer's Disease

...ology companies since beginning their seed fund in 1999. Those companies have gone on to raise over $600 million in additional capital from a diverse set of VCs, private investors, strategic partners and other sources of capital. ...

Velos, Inc. Releases Software to Support Cancer Centers With New Workflow and Content for NCI Clinical Trials Reporting Program

...ase may contain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. * U.S. News & World Report , Best Hospitals Survey ...

Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center

...; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to ref...

Elbit Imaging Ltd. Announces - Swiss Team Uses InSightec's ExAblate(R) 4000 Brain System to Treat Patients With Functional Brain Disorders

...EO of InSightec. "The results of this study set the ground for extensive brain study addressing th...factors including, without limitation, the factors set forth in our filings with the Securities and Excha...ied in their entirety by the cautionary statements set forth in our filings with the Securities and Excha...

University of Michigan Study Shows SEQUENOM's MassARRAY Technology Identifies HPV Infections Missed by Standard Hybridization Test

...4 CA080846 (MTR), K07 CA120040 (DAP)]. Forward-Looking Statements Except for the historical information contained herein, the matters set forth in this press release, including statements regarding potential false negatives and such potential false negatives leading to cervical cancer, ...

CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series

...latory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K/A for the year ended September 30,...

Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast Cancer

...is provided by proliferation. MapQuantTM Genomic Grade is available to European oncologists and pathologists. The genomic grade test analyzes a set of 97 genes to precisely quantify the proliferation potential of the tumor, and has been validated in several studies, covering more than 2 800 tumor ...

Why Do African-Americans Fare Worse With Cancer? Access and Economics Are Only Part of the Story

...of Clinical Oncology, the field's premier professional organization, recently issued a "Disparities in Cancer Care" policy statement that recommends a set of strategies for improving outcomes for minority cancer patients. "The elimination of socioeconomic and healthcare access disparities must be a ...

June 2009 Mayo Clinic Women's HealthSource Highlights Summer Skin Problems, Low Vision and Pilates

... seat and a series of springs and pulleys that allow progressive exercises to strengthen all muscle groups. A typical Pilates session includes a set of controlled stretches and movements, with participants concentrating on breathing, precision and flowing movements. Instead of emphasizing quantity,...

Leading Experts Endorse Bioheart's Muscle Stem Cell MyoCell Therapy

...ers are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements. These risk factors include, without limitation, (i) our ability to obtain additional financing; (ii) our abil...

Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder

...al conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or a...

MJFF's Rapid Response Innovation Awards Hit Mid-2009 With Over $1 Million Funded in High-Risk/High-Reward Approaches to Parkinson's Disease

...ective gene called DJ-1 in the brain. Dr. Freed is studying 12 people with recently diagnosed PD to determine if the drug can increase DJ-1 levels and set the stage for determining whether phenylbutyrate may slow disease progression. Richard Smeyne, PhD, of Saint Jude Children's Research Hospital...

Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease

... with FDA around the design of this pivotal study and are confident we have set the stage for a successful Phase 3 study. We continue to believe that Amig...results of clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the bu...

Cordex Signs European Development Partnership for ATPotent(TM) Sperm Motility Drug

...ted PSVT market. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Such risks include the risk that the data derived from the trials may not be sufficient to support...

Inspiration for 'My Sister's Keeper' Speaks Out

...ofessional sports teams will have to look elsewhere. He's our special boy, but he's just a kid." Lisa is emphatic about the parameters the couple set when working with Dr. Schoolcraft. "We decided Adam's cord blood would be used to attempt to save Molly's life, but that would be it. He would not be ...

Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia

...al conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or a...

New Safety Regulations Drive Greater Need for Resources and Expertise at Every Stage of Clinical Development

...o go beyond simply satisfying regulatory requirements, leading to more clinically effective and commercially viable advances that improve outcomes and set new standards of care." Notes to editors Survey methodology ICON commissioned IMS Health to conduct a survey that explored global...

MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes

...nts of novel biologics for autoimmune disorders, cancer and infectious diseases. Since its founding in 2000, the company has built a fully-integrated set of capabilities in monoclonal antibody product development. The company's product development efforts leverage three proprietary technology platforms...

New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring

...." PVI is available as part of Masimo Rainbow set Pulse CO-Oximetry(TM)--the first-and-only technolo...dependent and objective studies demonstrate Masimo set provides the most reliable SpO2 and pulse rate mea...fusion. In 2005, Masimo introduced Masimo Rainbow set Pulse CO-Oximetry, a breakthrough noninvasive bloo...

VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease

...l forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above. Forward-looking statements speak only as of the date they are made, and VIA undertakes no obligation to update publicly any of these stat...

ThermoGenesis Announces National Institute of Health Grant

...omplete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from ti...